This story has been bumping around in the online papers in India since Sunday night — but I’ve been waiting, for Whitehouse Station to confirm it, before running it:
. . . .The spokesperson for MSD Pharmaceuticals confirmed the development. “I can only confirm that research partnership has ended, but I cannot tell the reasons for it. . . .”
The billionaire brothers who founded Ranbaxy sold their stakes in the days after this deal was signed in 2008. Thus, it is at least possible that the subtle “pay to delay” side-effects — flowing from this deal — were considered by Merck to be no longer operative. And so, it was terminated.